Intellia Therapeutics, Inc.
NTLA
$13.39
-$0.09-0.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 67.01% | -3.25% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 67.01% | -3.25% | |||
| Cost of Revenue | -6.74% | -1.97% | |||
| Gross Profit | 22.34% | 1.69% | |||
| SG&A Expenses | 3.87% | 5.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.82% | 0.82% | |||
| Operating Income | 11.45% | -1.35% | |||
| Income Before Tax | 5.47% | -0.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.47% | -0.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.47% | -0.07% | |||
| EBIT | 11.45% | -1.35% | |||
| EBITDA | 11.67% | -1.43% | |||
| EPS Basic | 10.15% | 5.79% | |||
| Normalized Basic EPS | 16.31% | 3.87% | |||
| EPS Diluted | 10.15% | 5.79% | |||
| Normalized Diluted EPS | 16.31% | 3.87% | |||
| Average Basic Shares Outstanding | 5.20% | 6.22% | |||
| Average Diluted Shares Outstanding | 5.20% | 6.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||